EOM Pharmaceuticals (IMUC) News Today $0.16 +0.00 (+0.06%) As of 01/21/2025 01:11 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartFinancialsSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Q32 Bio Inc. R (DB0.BE)January 15, 2025 | finance.yahoo.comImmunoCellular Therapeutics, Ltd. (IMUC)January 5, 2024 | uk.finance.yahoo.comEOM Pharmaceutical Holdings Inc.December 29, 2023 | wsj.comEOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613November 7, 2023 | finance.yahoo.comIZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 YearsNovember 4, 2023 | markets.businessinsider.comImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives RevenuesNovember 3, 2023 | msn.comOramed Pharmaceuticals Inc ORMPNovember 1, 2023 | morningstar.comAnalyst Ratings for Olema PharmaceuticalsOctober 11, 2023 | markets.businessinsider.comEOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in BrazilSeptember 6, 2023 | finance.yahoo.comQ2 2023 PAVmed Inc Earnings CallAugust 17, 2023 | uk.finance.yahoo.comEOM Pharmaceuticals shelves plans to uplist shares, raise $15MAugust 3, 2023 | msn.comAcumen Pharmaceuticals Announces Proposed Public Offering of Common StockJuly 17, 2023 | benzinga.comAmneal Pharmaceuticals: FDA Requests Additional Information on IPX203 IngredientJuly 3, 2023 | marketwatch.comAmneal Pharmaceuticals Gets FDA Approval for Injectable Tumor TreatmentJune 14, 2023 | marketwatch.comTrade commission fights Amgen's $28B purchase of Horizon TherapeuticsMay 16, 2023 | msn.comPharma CEOs to testify in U.S. Senate hearing on insulin pricesMay 10, 2023 | msn.com8-K: Acumen Pharmaceuticals, Inc.May 10, 2023 | marketwatch.comOlema Pharmaceuticals GAAP EPS of -$0.70 misses by $0.04May 9, 2023 | msn.comOliX Pharmaceuticals Inc (226950)May 9, 2023 | investing.comUSFDA gives final nod to Alembic Pharmaceuticals’ Glaucoma drugMarch 30, 2023 | msn.comU.S. Supreme Court mulls Amgen bid to revive cholesterol drug patentsMarch 27, 2023 | reuters.comRegeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gainsMarch 13, 2023 | marketwatch.comEOM Pharmaceuticals Holdings, Inc. (IMUC)March 11, 2023 | finance.yahoo.comIonis Pharmaceuticals, Inc. (IONS) Q4 2022 Earnings Call TranscriptFebruary 24, 2023 | seekingalpha.comAltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological DiseasesDecember 8, 2022 | technews.tmcnet.comAlaunos Therapeutics Shares Drop 24% After Public Offering PricesNovember 29, 2022 | marketwatch.comInVivo Therapeutics Adds to Surge After Hours, Recently at $10.85October 6, 2022 | marketwatch.comImunon Appoints James E. Dentzer to its Board of DirectorsOctober 3, 2022 | benzinga.comSeres Therapeutics Inc MCRB Stock QuoteSeptember 21, 2022 | morningstar.comImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics ConferenceSeptember 14, 2022 | benzinga.comImmunoCellular Therapeutics LtdSeptember 11, 2022 | reuters.comEOM Pharmaceutical Files For $25 Million IPO Uplisting To NasdaqJune 28, 2022 | seekingalpha.comEOM Pharmaceuticals files to uplist to NasdaqJune 24, 2022 | seekingalpha.comEOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger AgreementDecember 2, 2021 | finance.yahoo.com Get EOM Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUC and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUC Media Mentions By Week IMUC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUC News Sentiment▼0.000.63▲Average Medical News Sentiment IMUC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUC Articles This Week▼00▲IMUC Articles Average Week Get EOM Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PYRGF News THTX News APLT News CUE News INCR News MRSN News GNTA News TLSA News XTNT News ALLK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IMUC) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget 99.999% of Stocks… Do This insteadThis might sound crazy to say... But FORGET most stocks. Because I have a different strategy... One t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EOM Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EOM Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
